Semax plus heparin: antithrombotic composition — RU2138269C1
И.П. Ашмарин, Л.А. Ляпина, В.Е. Пасторова, А.А. Каменский, В.И. Скворцова, Н.Ф. Мясоедов · 1999 · RU2138269C1 · patent family 20199624
Published 1999-09-27.
Reported patent results
Reported findings
The combination produced anticoagulant and antiplatelet effects in laboratory tests.
Semax–heparin complex tested in rat plasma and animal thrombosis experiments; no human anticoagulation trial.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Thrombin time | 45.5 seconds with the complex versus 28.7 seconds with the heparin comparison | Rat plasma clotting assay; longer is not an established clinical benefit |
| Platelet aggregation | Reported reduction from a 100% reference to 15% | Experimental combination result; group denominator not supplied in the extracted narrative |
| Experimental thrombosis mortality | 16% with the combination versus 40% saline control | Animal challenge; no verified human risk estimate |
The effects concern the complex, not Semax alone. Small incompletely reported animal experiments do not establish clinical effectiveness, bleeding safety or an appropriate human regimen.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Formulation. The claims concern an antithrombotic combination involving Semax and heparin.
A combined composition cannot demonstrate Semax-alone efficacy or justify unsupervised anticoagulant treatment.
- Publication
- RU2138269C1 ↗ · 1999-09-27
- Earliest priority / filing
- 1997-12-04 / 1997-12-04
- Original applicant / assignee
- Ашмарин Игорь Петрович; Ляпина Людмила Анисимовна; Пасторова Валентина Ефимовна; Каменский Андрей Александрович; Скворцова Вероника Игоревна; Мясоедов Николай Федорович
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20199624 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Antithrombosis agent
Inventors: И.П. Ашмарин; Л.А. Ляпина; В.Е. Пасторова; А.А. Каменский; В.И. Скворцова; Н.Ф. Мясоедов.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- A combined composition cannot demonstrate Semax-alone efficacy or justify unsupervised anticoagulant treatment.
- The effects concern the complex, not Semax alone. Small incompletely reported animal experiments do not establish clinical effectiveness, bleeding safety or an appropriate human regimen.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-20199624. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: И.П. Ашмарин, Л.А. Ляпина, В.Е. Пасторова, А.А. Каменский, В.И. Скворцова, Н.Ф. Мясоедов. Semax plus heparin: antithrombotic composition — RU2138269C1 RU2138269C1 · patent family 20199624 1999.
Molekul research summary: https://molekul.io/research/patent-ru2138269c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry